pyrimidin-2-one beta-ribofuranoside has been researched along with Burkitt Lymphoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, C; Bernasconi, M; Nadal, D; Rao, SP; Rechsteiner, MP; Sigrist, JA | 1 |
1 other study(ies) available for pyrimidin-2-one beta-ribofuranoside and Burkitt Lymphoma
| Article | Year |
|---|---|
Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells.
Topics: Antineoplastic Agents; Azacitidine; Burkitt Lymphoma; Cadherins; Cytidine; Gene Silencing; Herpesvirus 4, Human; Humans; Tumor Cells, Cultured; Virus Latency | 2007 |